{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:45:06Z","timestamp":1792586706731,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Health and Medical Research Council of Australia","award":["1135820"],"award-info":[{"award-number":["1135820"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tropical Australia has a high incidence of nocardiosis, with high rates of intrinsic antimicrobial resistance. Linezolid, the only antimicrobial to which all local Nocardia species are susceptible, has been recommended in empirical combination treatment regimens for moderate\u2013severe Nocardia infections at Royal Darwin Hospital (RDH) since 2014. We report the safety and efficacy of linezolid use for nocardiosis in this setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified cases through a retrospective review of all RDH Nocardia isolates from December 2014 to August 2018 and included 5 linezolid-treated cases from a previous cohort. Laboratory, demographic, and clinical data were included in the primary analysis of safety and treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2014 and 2018, Nocardia was isolated from 35 individuals; 28 (80%) had clinically significant infection and 23 (82%) received treatment. All isolates were linezolid-susceptible. Safety and efficacy were assessed for 20 patients receiving linezolid-containing regimens and 8 receiving nonlinezolid regimens. Median linezolid induction therapy duration was 28 days. Common adverse effects in those receiving linezolid were thrombocytopenia (45%) and anemia (40%). Adverse events prompted discontinuation of trimethoprim-sulfamethoxazole more often than linezolid (40% vs 20%). Linezolid therapeutic drug monitoring was used in 1 patient, with successful dose reduction and outcome. There was no difference in 30-day survival between those treated with linezolid (90%) vs no linezolid (87%). One Nocardia-attributed death occurred during linezolid therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Linezolid is safe and efficacious in empirical treatment for moderate to severe nocardiosis in a monitored hospital setting, with 100% drug susceptibility and no difference in adverse events or outcomes compared with nonlinezolid regimens.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofaa090","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T04:27:34Z","timestamp":1584332854000},"source":"Crossref","is-referenced-by-count":43,"title":["Safety and Outcomes of Linezolid Use for Nocardiosis"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4829-9905","authenticated-orcid":false,"given":"Natalie","family":"Davidson","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Royal Darwin Hospital, Darwin, NT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Grigg","sequence":"first","affiliation":[{"name":"Menzies School of Health Research, Darwin, NT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Mcguinness","sequence":"first","affiliation":[{"name":"Monash University, Melbourne, Vic, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Baird","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Royal Darwin Hospital, Darwin, NT, Australia"},{"name":"Department Microbiology, Royal Darwin Hospital, Darwin, NT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M","family":"Anstey","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Royal Darwin Hospital, Darwin, NT, Australia"},{"name":"Menzies School of Health Research, Darwin, NT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"2020040114350667000_CIT0001","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.micpath.2017.11.012","article-title":"Nocardiosis from 1888 to 2017","volume":"114","author":"Fatahi-Bafghi","year":"2018","journal-title":"Microb Pathog"},{"issue":"(4)","key":"2020040114350667000_CIT0002","first-page":"XXX\u2013XX","article-title":"Nocardiosis in the tropical Northern Territory of Australia, 1997\u20132014","volume":"3","author":"McGuinness","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2020040114350667000_CIT0003","first-page":"2853","article-title":"Nocardia spp.","volume-title":"Principles and Practice of Infectious Diseases","author":"Sorell","year":"2016","edition":"8th ed."},{"key":"2020040114350667000_CIT0004","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/514340","article-title":"Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020040114350667000_CIT0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1227\/00006123-199410000-00007","article-title":"Nocardial brain abscess: treatment strategies and factors influencing outcome","volume":"35","author":"Mamelak","year":"1994","journal-title":"Neurosurgery"},{"key":"2020040114350667000_CIT0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/imj.14068","article-title":"Nocardiosis: 7-year experience at an Australian tertiary hospital","volume":"49","author":"Paige","year":"2019","journal-title":"Intern Med J"},{"key":"2020040114350667000_CIT0007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.45.4.1295-1297.2001","article-title":"In vitro activities of linezolid against multiple Nocardia species","volume":"45","author":"Brown-Elliott","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020040114350667000_CIT0008","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/345907","article-title":"Clinical experience with linezolid for the treatment of Nocardia infection","volume":"36","author":"Moylett","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020040114350667000_CIT0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jinf.2014.08.010","article-title":"Experience with linezolid for the treatment of nocardiosis in organ transplant recipients","volume":"70","author":"De La Cruz","year":"2015","journal-title":"J Infect"},{"key":"2020040114350667000_CIT0010","doi-asserted-by":"crossref","first-page":"e01419","DOI":"10.1128\/JCM.01419-17","article-title":"The complexities of Nocardia taxonomy and identification","volume":"56","author":"Conville","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2020040114350667000_CIT0011","first-page":"45","article-title":"Susceptibility testing of mycobacteria, Nocardia spp. and other aerobic actinomycetes; approved standard","volume-title":"CLSI Document M24","author":"CLSI","year":"2018","edition":"3rd ed"},{"key":"2020040114350667000_CIT0012","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"2020040114350667000_CIT0013","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020040114350667000_CIT0014","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1128\/JCM.06243-11","article-title":"Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey","volume":"50","author":"Brown-Elliott","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020040114350667000_CIT0015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/657399","article-title":"Antimicrobial-resistant Nocardia isolates, United States, 1995\u20132004","volume":"51","author":"Uhde","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020040114350667000_CIT0016","doi-asserted-by":"crossref","first-page":"43660","DOI":"10.1038\/srep43660","article-title":"Susceptibility profiles of Nocardia spp. to antimicrobial and antituberculotic agents detected by a microplate Alamar Blue assay","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"key":"2020040114350667000_CIT0017","doi-asserted-by":"crossref","first-page":"e13509","DOI":"10.1111\/ctr.13509","article-title":"Nocardia infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation","volume":"33","author":"Restrepo","year":"2019","journal-title":"Clin Transplant"},{"key":"2020040114350667000_CIT0018","article-title":"Nocardiosis","volume-title":"eTG Complete","author":"Antibiotic Expert Group"},{"key":"2020040114350667000_CIT0019","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1128\/AAC.00051-06","article-title":"Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients","volume":"50","author":"Myrianthefs","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020040114350667000_CIT0020","first-page":"1749691","article-title":"Nocardia spp. pneumonia in a solid organ recipient: role of linezolid","volume":"2018","author":"Mwandia","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"2020040114350667000_CIT0021","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/clinids\/22.6.891","article-title":"Nocardiosis","volume":"22","author":"Lerner","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020040114350667000_CIT0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ajt.12102","article-title":"Nocardia infections in solid organ transplantation","volume":"13(Suppl 4)","author":"Clark","year":"2013","journal-title":"Am J Transplant"},{"key":"2020040114350667000_CIT0023","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1128\/AAC.00135-12","article-title":"Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy","volume":"56","author":"Pea","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020040114350667000_CIT0024","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020040114350667000_CIT0025","volume-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update","author":"WHO","year":"2016"},{"key":"2020040114350667000_CIT0026","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMed"},{"key":"2020040114350667000_CIT0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425255.2016.1166204","article-title":"Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones","volume":"12","author":"Cattaneo","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2020040114350667000_CIT0028","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020040114350667000_CIT0029","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020040114350667000_CIT0030","doi-asserted-by":"crossref","first-page":"e00605","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020040114350667000_CIT0031","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2020040114350667000_CIT0032","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020040114350667000_CIT0033","doi-asserted-by":"crossref","first-page":"0903","DOI":"10.1183\/13993003.00580-2019","article-title":"Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300\u2005mg linezolid dosages using in-house made capsules","volume":"54","author":"Bolhuis","year":"2019","journal-title":"Eur Respir J"},{"key":"2020040114350667000_CIT0034","volume-title":"Opportunistic Infetions Prevention in Patients on Immunosupression TEHS Guideline","author":"Marshall","year":"2017"},{"key":"2020040114350667000_CIT0035","doi-asserted-by":"crossref","first-page":"e12902","DOI":"10.1111\/tid.12902","article-title":"Nocardia infections in the transplanted host","volume":"20","author":"Hemmersbach-Miller","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2020040114350667000_CIT0036","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ekir.2017.09.005","article-title":"Trimethoprim+sulfamethoxazole reduces rates of melioidosis in high-risk hemodialysis patients","volume":"3","author":"Majoni","year":"2018","journal-title":"Kidney Int Rep"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa090\/32907112\/ofaa090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/4\/ofaa090\/32988238\/ofaa090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/4\/ofaa090\/32988238\/ofaa090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T21:28:45Z","timestamp":1666128525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa090\/5805505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa090","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,3,16]]},"article-number":"ofaa090"}}